Immunovant Stock Investor Trims Stake, Still Bullish
Immunovant stock surged about 30% after a fund trimmed its stake by roughly $3 million. This article explains why the...
Understanding which risk dominates can guide your allocation decisions. This comparison highlights when inflation worry or market dips matter more.
28,524 articlesImmunovant stock surged about 30% after a fund trimmed its stake by roughly $3 million. This article explains why the...
A big trade in a technology-focused ETF last quarter offers more than a headline. This article digs into what investo...
Regulators are weighing changes to mortgage asset rules, yet banks may take time to adjust. In the near term, mortgag...
The U.S. is expanding its military footprint in the Middle East, adding three amphibious ships and 2,500 Marines. Mar...
Step inside a thoughtful millionaire interview to uncover the habits, investments, and routines that help people grow...
Oracle's latest guidance sparked a sell-off as investors weigh AI-driven capital outlays against cash flow. This arti...
When Nasdaq and S&P 500 slip together into correction territory, investors face questions and tough choices. This gui...
Navitas Semiconductor is pursuing an AI data-center power strategy built around 800V architecture. This move could re...
In June, Lemonade stock surged about 12% as investors weighed progress on its reinsurance strategy and AI-driven grow...
For years, SK Hynix has traded at a discount to Micron. This article explains why the gap exists, what could close it...
A renewed policy debate on redistributing elon musk’s trillion raises questions about liquidity, feasibility, and the...
XCEM has risen 38% year-to-date, beating the S&P 500 by a wide margin as investors tilt toward emerging markets ex-Ch...